• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom, Lilly partner on diabetes management for healthcare providers

October 7, 2020 By Nancy Crotti

Eli Lilly (NYSE:LLY) and Dexcom (NSDQ:DXCM) today announced a joint program for U.S. healthcare providers that includes Lilly’s new, rapid-acting Lyumjev mealtime insulin pen and Dexcom G6 continuous glucose monitoring (CGM) systems.

The program is designed to help clinicians use data to inform diabetes management, including promoting  the benefits of a new mealtime insulin dose, the companies said in a news release. Lyumjev is a novel formulation of insulin lispro, which Lilly said was developed to speed the absorption of insulin into the bloodstream and reduce A1C levels in adults with diabetes.

Healthcare providers treating type 1 and type 2 diabetes will be able to assess their patients’ glucose levels and time in range with Dexcom G6 or Dexcom G6 Pro, either in blinded or unblinded mode, helping them quickly identify adult patients who struggle to manage their glucose levels following meals (postprandial glucose, or PPG), according to the companies. Postprandial glucose is often overlooked as a significant contributor to a patient’s average blood sugar level or A1C, according to a study published in 2019 by the American Diabetes Association.

Indianapolis-based Lilly and San Diego-based Dexcom are also promoting PPG monitoring as a component of diabetes treatment management. The companies announced a separate partnership in December.

“When it comes to treating diabetes, our partnership with Dexcom has the potential to be meaningful for (healthcare providers) who want to help their patients who may be struggling to manage their blood glucose levels after meals,” said Adrienne Brown, Lilly’s VP of U.S. diabetes and connected care.  “Through this program, we can inspire confidence as clinicians and their patients evaluate new treatment options by showcasing how using these resources together can inform diabetes care.”

“We are thrilled to partner once again with a leader in diabetes care like Lilly,” said Rick Doubleday, chief commercial officer at Dexcom. “Our goal is that the real-time data provided through Dexcom G6 and Dexcom G6 Pro will allow healthcare providers to help their patients with diabetes make more informed decisions, measure and evaluate their time in range, and have more visibility to the potential benefits of transitioning to a new mealtime insulin such as Lyumjev.”

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Pharmaceuticals Tagged With: Dexcom, Eli Lilly & Co.

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS